Abstract
BackgroundAtezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or UC with mixed variant histology (MVH) is not well characterized.ObjectiveTo report...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have